Conclusions
REMISSION
In this comparative effectiveness study, DAS28-CRP was significantly lower at 3 months for patients treated with TOF compared with ADA. However, 3 months of treatment with either drug led to substantive reductions in mean DAS28-CRP, consistent with remission. There was no difference in DAS28-CRP between patients receiving TOF or ADA at 9 months. The results of this observational study are consistent with clinical trial data